When dealing with Polycythemia Vera, a chronic blood disorder that makes the bone marrow churn out too many red blood cells, thickening the blood and raising clot risk. Also known as PV, it belongs to the family of myeloproliferative neoplasms, and most patients carry a JAK2 mutation that drives the overproduction.
Typical signs show up slowly. You might feel constant fatigue, get itchy after a hot shower, or notice headaches and dizziness. Some people develop a ruddy complexion or notice their spleen swelling. A simple complete blood count (CBC) often flags the high red‑cell mass, but doctors confirm the diagnosis with a bone‑marrow biopsy and genetic testing for the JAK2 V617F mutation. These steps help separate PV from other causes of high hemoglobin.
Treatment starts with the basics: regular phlebotomy to keep the hematocrit below 45%, and low‑dose aspirin to thin the blood a bit. When phlebotomy isn’t enough, cytoreductive drugs step in. Hydroxyurea is the most common first‑line medicine; it curbs marrow production and reduces clot risk. For patients who can’t tolerate hydroxyurea or need a stronger approach, a JAK inhibitor such as ruxolitinib is often prescribed. These drugs target the same molecular pathway that the JAK2 mutation activates.
Beyond medication, managing complications is crucial. PV raises the chance of deep‑vein thrombosis, stroke, and heart attacks, so regular monitoring of blood counts and cardiovascular health is a must. Splenomegaly can cause abdominal discomfort; if it becomes severe, doctors may consider interferon‑alpha or even surgical removal, though that’s rare. Lifestyle tweaks—staying hydrated, avoiding smoking, and keeping a healthy weight—help keep blood viscosity in check. Many patients also benefit from a daily low‑dose aspirin regimen, unless bleeding disorders are present.
Because treatment often requires long‑term medication, keeping costs manageable matters. Our site offers guidance on buying generic versions of hydroxyurea, ruxolitinib, and related drugs safely online. Look for licensed Canadian pharmacies, double‑check the prescription requirement, and compare prices before you order. Affordable access lets you stay on therapy without interruption, which is key for preventing clots and controlling symptoms.
Research continues to bring new options. Pegylated interferon, fedratinib, and newer JAK inhibitors are in various trial stages, aiming for better efficacy with fewer side effects. If you’re curious about clinical trials, talk to your hematologist—they can match you with studies that fit your health profile.
Now that you’ve got a solid overview of polycythemia vera—its causes, how doctors spot it, and the main ways to keep it under control—explore the articles below. You’ll find deeper dives on medication safety, lifestyle tips, and the latest research that can help you stay ahead of the disease.
